Oramed Pharmaceuticals Inc.
Tel Aviv Stock ExchangeTotal Valuation
Oramed Pharmaceuticals Inc. carries a market capitalization of 562.73M, placing it among publicly traded companies globally. Its enterprise value stands at 13.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 562.73M |
| Enterprise Value | 13.77B |
Share Statistics
Oramed Pharmaceuticals Inc. currently has 40.93M shares outstanding.
| Shares Outstanding | 40.93M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Oramed Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 125.77.
| PE Ratio | 125.77 |
| PS Ratio | N/A |
| PB Ratio | -163.48 |
| P/TBV Ratio | 58.06 |
| P/FCF Ratio | -2,146.26 |
| P/OCF Ratio | -1,619.86 |
Financial Position
Oramed Pharmaceuticals Inc. maintains a current ratio of 6.45, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.45 |
| Quick Ratio | 6.23 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 52.84 |
| Return on Invested Capital (ROIC) | -6.11 |
| Return on Capital Employed (ROCE) | -82.04 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Oramed Pharmaceuticals Inc. has paid 21.85M in income taxes, reflecting an effective tax rate of 16.58.
| Income Tax | 21.85M |
| Effective Tax Rate | 16.58 |
Stock Price Statistics
Oramed Pharmaceuticals Inc.'s stock has gained approximately 89.18547% over the past 52 weeks. The 50-day moving average sits at 838.38, while the 200-day moving average is 216.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | 89.18547% |
| 50-Day Moving Average | 838.38 |
| 200-Day Moving Average | 216.80 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -14.13M, while operating income came in at -14.25M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -14.25M |
| Pretax Income | 131.82M |
| Net Income | 110.00M |
| EBITDA | -14.13M |
| EBIT | -14.25M |
| Earnings Per Share (EPS) | 2.59 |
Balance Sheet
Oramed Pharmaceuticals Inc. holds 65.84M in cash and equivalents against 761,000.00 in total debt, resulting in a net debt position of -13.20M. Total book value stands at -84.63M, with working capital of 57.59M providing operational flexibility.
| Cash & Cash Equivalents | 65.84M |
| Total Debt | 761,000.00 |
| Net Debt | -13.20M |
| Equity (Book Value) | -84.63M |
| Book Value Per Share | -2.04 |
| Working Capital | 57.59M |
Cash Flow
Oramed Pharmaceuticals Inc. produced -8.54M in operating cash flow over the past twelve months. After subtracting -1.93M in capital expenditures, free cash flow totaled -10.48M - equivalent to -0.25 per share.
| Operating Cash Flow | -8.54M |
| Capital Expenditures | -1.93M |
| Free Cash Flow | -10.48M |
| FCF Per Share | -0.25 |
Dividends & Yields
The company's payout ratio of 9.43 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.25 |
| Dividend Yield | N/A |
| Payout Ratio | 9.43 |
| Shareholder Yield | 0.11 |
| FCF Yield | -0.05 |
Scores
Oramed Pharmaceuticals Inc. posts an Altman Z-Score of 271.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 271.18 |